Award Data

This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

Tetra Discovery Partners was the recipient of an NIH Blueprint Neurotherapeutics Network award to develop a phosphodiesterase-4D (PDE4D) allosteric inhibitor for treating cognitive impairment in patients affected by psychiatric and neurologic diseases. The Tetra-NIH Blueprint drug, BPN14770, currently is in human Phase 2 clinical trials for the treatment of Fragile X Syndrome and Alzheimer’s dis ...

Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

Recent advances in DNA sequencing technology have not been matched by improved analytic techniques to quickly and accurately interpret patient genome data to inform diagnosisprognosis and therapy making decisions in the clinic and to identify candidate biomarkers of disease in research laboratoriesDevelopment of automated techniques to facilitate interpretation of this data will benefit patient ca ...

Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...

PROJECT SUMMARYABSTRACT In Phase IBiocrede developed a wirelessFrflexibleand aFrdual lumencatheternitric oxideNOreleasingin vivo tested without heparin injectionscontinuous lactate sensor that can wirelessly monitor intravenousIVblood lactate levels to alert caregivers in the ICU when lactate levels riseElevated blood lactate levels are associated with major morbidity and mortality in critically i ...

The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...